89 related articles for article (PubMed ID: 24805134)
1. The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability.
Nolan S; Arnason T; Drucker A; Huang WY
Appl Immunohistochem Mol Morphol; 2014; 22(5):e8-e13. PubMed ID: 24805134
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
Kuan SF; Navina S; Cressman KL; Pai RK
Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
[TBL] [Abstract][Full Text] [Related]
4. BRAFV600E Gene Mutation in Colonic Adenocarcinomas. Immunohistochemical Detection Using Tissue Microarray and Clinicopathologic Characteristics: An 86 Case Series.
Boulagnon C; Dudez O; Beaudoux O; Dalstein V; Kianmanesh R; Bouché O; Diebold MD
Appl Immunohistochem Mol Morphol; 2016 Feb; 24(2):88-96. PubMed ID: 25710585
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test.
Hang JF; Li AF; Chang SC; Liang WY
Histopathology; 2016 Jul; 69(1):54-62. PubMed ID: 26588428
[TBL] [Abstract][Full Text] [Related]
6. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.
Toon CW; Walsh MD; Chou A; Capper D; Clarkson A; Sioson L; Clarke S; Mead S; Walters RJ; Clendenning M; Rosty C; Young JP; Win AK; Hopper JL; Crook A; von Deimling A; Jenkins MA; Buchanan DD; Gill AJ
Am J Surg Pathol; 2013 Oct; 37(10):1592-602. PubMed ID: 23797718
[TBL] [Abstract][Full Text] [Related]
7. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M
Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
[TBL] [Abstract][Full Text] [Related]
8. A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial.
Roth RM; Hampel H; Arnold CA; Yearsley MM; Marsh WL; Frankel WL
Am J Clin Pathol; 2015 Mar; 143(3):336-43. PubMed ID: 25696791
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation in sporadic colorectal cancer and Lynch syndrome.
Thiel A; Heinonen M; Kantonen J; Gylling A; Lahtinen L; Korhonen M; Kytölä S; Mecklin JP; Orpana A; Peltomäki P; Ristimäki A
Virchows Arch; 2013 Nov; 463(5):613-21. PubMed ID: 23963522
[TBL] [Abstract][Full Text] [Related]
10. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
[TBL] [Abstract][Full Text] [Related]
11. BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.
Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
JAMA Dermatol; 2015 Apr; 151(4):410-6. PubMed ID: 25588152
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of BRAF V600E Mutations in High-Level Microsatellite Instability(MSI-H)Colon Cancer - Comparison Between Genetic Testing and Immunohistochemical Staining].
Sakimoto T; Chika N; Suzuki O; Ishibashi K; Tachikawa T; Akagi K; Eguchi H; Okazaki Y; Ishida H
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1693-1695. PubMed ID: 28133101
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
Chouhan H; Sammour T; L Thomas M; W Moore J
Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms.
Vakiani E; Yaeger R; Brooke S; Zhou Y; Klimstra DS; Shia J
Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):438-43. PubMed ID: 25517872
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia.
Brown NA; Betz BL; Weigelin HC; Elenitoba-Johnson KS; Lim MS; Bailey NG
Am J Clin Pathol; 2015 Jan; 143(1):89-99. PubMed ID: 25511147
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
[TBL] [Abstract][Full Text] [Related]
20. Assessment of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in benign and malignant salivary gland neoplasms.
Bodnar M; Burduk P; Antosik P; Jarmuz-Szymczak M; Wierzbicka M; Marszalek A
J Oral Pathol Med; 2017 May; 46(5):340-345. PubMed ID: 27682157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
